RxDoctor Payments Data

Leanne Strack, DO

Pulmonary Disease · Sandusky, OHNPI 1982653432

Payments from drug & device makers

$3,530in general payments, 2019–2025

Across 168 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$748
  • GSK$627
  • Sanofi$529
  • Mylan Specialty L.p.$309
  • Regeneron Healthcare Solutions, Inc.$239
  • Actelion Pharmaceuticals US, Inc.$226
  • plus $853 from 15 others

What the payments were for

  • Food & beverage$3,29993%
  • Education$2317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,530 in reported general payments places this provider in the 55th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$129,814
Medicare patients
302
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter241$212,840
Dupixent PenDupilumab20$74,045
Breztri AerosphereBudesonide/Glycopyr/Formoterol92$69,502
Spiriva RespimatTiotropium Bromide57$31,535
Breo ElliptaFluticasone/Vilanterol31$15,363
DuleraMometasone/Formoterol14$7,018
Combivent RespimatIpratropium/Albuterol Sulfate13$6,200
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,927
Albuterol Sulfate HfaAlbuterol Sulfate184$4,925
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,324
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$2,828
Ventolin HfaAlbuterol Sulfate39$2,437
Proair RespiclickAlbuterol Sulfate23$2,412
Roflumilast28$1,289
Azithromycin54$641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$627$228,204272 claims
AstraZenecaBreztri Aerosphere$748$69,50292 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$138$43,66281 claims
MerckDulera$47$7,01814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →